NASDAQ:MRTX

Mirati Therapeutics - MRTX Stock Forecast, Price & News

$36.54

-1.04 (-2.77%)

(As of 03/28/2023 12:00 AM ET)

Add

Compare

Today's Range: $36.27
▼
$38.19
50-Day Range: $37.58
▼
$54.26
52-Week Range: $32.96
▼
$101.30

Volume: 1.18 million shs
Average Volume: 1.18 million shs
Market Capitalization: $2.12 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $80.87

Institutional Ownership

Mirati Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.46 Rating Score
Upside/Downside: 121.3% Upside
$80.87 Price Target
Short Interest: Bearish
14.82% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.68
Upright™ Environmental Score
News Sentiment: 1.75
Based on 3 Articles This Week
Insider Trading: Selling Shares
$699,126 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($13.26) to ($11.46) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

362nd out of 1,002 stocks

Pharmaceutical Preparations Industry

162nd out of 488 stocks

3.2

Analyst's Opinion

Consensus Rating
Mirati Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 6 buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $80.87, Mirati Therapeutics has a forecasted upside of 121.3% from its current price of $36.54.
Amount of Analyst Coverage
Mirati Therapeutics has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
14.82% of the outstanding shares of Mirati Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Mirati Therapeutics has a short interest ratio ("days to cover") of 6.8.
Change versus previous month
Short interest in Mirati Therapeutics has recently decreased by 2.38%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Mirati Therapeutics does not currently pay a dividend.
Dividend Growth
Mirati Therapeutics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Mirati Therapeutics has received a 74.62% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for cancer", "Basic medical research services", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Mirati Therapeutics is -0.68.

3.7

News and Social Media Coverage

News Sentiment
Mirati Therapeutics has a news sentiment score of 1.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Mirati Therapeutics this week, compared to 2 articles on an average week.
Search Interest
14 people have searched for MRTX on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Mirati Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Mirati Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $699,126.00 in company stock.
Percentage Held by Insiders
Only 3.47% of the stock of Mirati Therapeutics is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Mirati Therapeutics are expected to grow in the coming year, from ($13.26) to ($11.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Mirati Therapeutics is -2.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Mirati Therapeutics is -2.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Mirati Therapeutics has a P/B Ratio of 2.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Mirati Therapeutics (NASDAQ:MRTX) Stock

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Stock News Headlines

March 19, 2023 | americanbankingnews.com

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Receives $80.87 Average Price Target from Brokerages

March 15, 2023 | msn.com

Strength Seen in Mirati (MRTX): Can Its 13.5% Jump Turn into More Strength?

March 28, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.

March 3, 2023 | benzinga.com

Mirati Therapeutics Stock (NASDAQ:MRTX), Guidance and Forecast

March 2, 2023 | finance.yahoo.com

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 36% Undervaluation?

February 16, 2023 | nasdaq.com

Avoro Capital Advisors Now Owns 9.60% of Mirati Therapeutics (MRTX)

February 14, 2023 | finance.yahoo.com

Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023

January 19, 2023 | finance.yahoo.com

Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133

March 28, 2023 | Behind the Markets (Ad)

Buy THIS stock before Taiwan is attacked

January 19, 2023 | finance.yahoo.com

We're Keeping An Eye On Mirati Therapeutics' (NASDAQ:MRTX) Cash Burn Rate

January 6, 2023 | benzinga.com

Kaskela Law LLC Announces Investigation of Mirati Therapeutics, Inc. (MRTX) and Encourages Long-Term MRTX Investors to Contact the Firm

December 22, 2022 | finance.yahoo.com

Mirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 22, 2022 | msn.com

Mirati's (MRTX) Krazati Gets Breakthrough Therapy Tag for CRC

December 14, 2022 | msn.com

Mirati draws Hold rating at Needham despite recent selloff

December 13, 2022 | baystreet.ca

Mirati Drops on Acceptance of Cancer Drug

December 13, 2022 | finance.yahoo.com

Mirati (MRTX) Up on FDA Nod to Adagrasib for KRAS Mutated NSCLC

December 9, 2022 | benzinga.com

Why Mirati Therapeutics Shares Are Nosediving

December 9, 2022 | finance.yahoo.com

These Analysts Think Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) Sales Are Under Threat

December 8, 2022 | benzinga.com

Why Mirati Therapeutics Shares Are Getting Hammered Again Today

December 7, 2022 | finance.yahoo.com

Why Shares of Mirati Therapeutics Fell Wednesday

December 7, 2022 | benzinga.com

Why Mirati Therapeutics Stock Is Trading Sharply Lower Today

December 7, 2022 | markets.businessinsider.com

SVB Securities Reaffirms Their Buy Rating on Mirati Therapeutics (MRTX)

December 6, 2022 | finance.yahoo.com

Mirati Experimental Lung Cancer Drug Shows Favorable Tolerability, Promising Efficacy

December 6, 2022 | finance.yahoo.com

Why Shares of Mirati Therapeutics Fell Tuesday

December 6, 2022 | finance.yahoo.com

Mirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats Up

December 6, 2022 | barrons.com

Premarket Movers: GitLab Cl A, Mirati Therapeutics, Textron

December 2, 2022 | finance.yahoo.com

Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MRTX Company Calendar

Last Earnings: 2/28/2023
Today: 3/28/2023
Next Earnings (Estimated): 5/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MRTX
CUSIP: N/A
CIK: 1576263
Web: www.mirati.com
Phone: (858) 332-3410
Fax: N/A
Employees: 413
Year Founded: 2013

Price Target and Rating

Average Stock Price Forecast: $80.87
High Stock Price Forecast: $188.00
Low Stock Price Forecast: $50.00
Forecasted Upside/Downside: +114.8%
Consensus Rating: Hold
Rating Score (0-4): 2.46
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($13.18)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-740,870,000.00
Net Margins: -5,957.44%
Pretax Margin: -5,953.35%
Return on Equity: -66.05%
Return on Assets: -56.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.95
Quick Ratio: 6.94

Sales & Book Value

Annual Sales: $12.44 million
Price / Sales: 175.66
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $17.31 per share
Price / Book: 2.18

Miscellaneous

Outstanding Shares: 58,040,000
Free Float: 56,024,000
Market Cap: $2.19 billion
Optionable: Optionable
Beta: 1.05

Social Links

Key Executives

David D. Meek
Chief Executive Officer & Director

Charles M. Baum
President, Director & Head-Research & Development

Laurie D. Stelzer
Chief Financial Officer

James G. Christensen
Chief Scientific Officer & Executive VP

Alan Bart Sandler
Chief Medical Officer & Executive Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MRTX Stock - Frequently Asked Questions

Should I buy or sell Mirati Therapeutics stock right now?: 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRTX, but not buy additional shares or sell existing shares.
View MRTX analyst ratings or view top-rated stocks.
What is Mirati Therapeutics' stock price forecast for 2023?: 13 brokerages have issued twelve-month price objectives for Mirati Therapeutics' shares. Their MRTX share price forecasts range from $50.00 to $188.00. On average, they predict the company's stock price to reach $80.87 in the next year. This suggests a possible upside of 114.8% from the stock's current price.
View analysts price targets for MRTX or view top-rated stocks among Wall Street analysts.
How have MRTX shares performed in 2023?: Mirati Therapeutics' stock was trading at $45.31 at the beginning of the year. Since then, MRTX shares have decreased by 16.9% and is now trading at $37.65.
View the best growth stocks for 2023 here.
When is Mirati Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our MRTX earnings forecast.
How were Mirati Therapeutics' earnings last quarter?: Mirati Therapeutics, Inc. (NASDAQ:MRTX) posted its quarterly earnings results on Tuesday, February, 28th. The biotechnology company reported ($3.51) earnings per share for the quarter, beating analysts' consensus estimates of ($3.74) by $0.23. The biotechnology company earned $0.93 million during the quarter, compared to analyst estimates of $2.65 million. Mirati Therapeutics had a negative net margin of 5,957.44% and a negative trailing twelve-month return on equity of 66.05%. The firm's revenue for the quarter was up 212.4% on a year-over-year basis. During the same period last year, the business earned ($3.72) EPS.
What ETFs hold Mirati Therapeutics' stock?: ETFs with the largest weight of Mirati Therapeutics (NASDAQ:MRTX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Virtus LifeSci Biotech Clinical Trials ETF (BBC), IQ U.S. Mid Cap R&D Leaders ETF (MRND), Principal Healthcare Innovators ETF (BTEC), BlackRock Future Health ETF (BMED) and Invesco Nasdaq Biotechnology ETF (IBBQ).
What other stocks do shareholders of Mirati Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

What is Mirati Therapeutics' stock symbol?: Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."
Who are Mirati Therapeutics' major shareholders?: Mirati Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (9.65%), Armistice Capital LLC (6.06%), Morgan Stanley (2.93%), Price T Rowe Associates Inc. MD (2.46%), Point72 Asset Management L.P. (1.31%) and Franklin Resources Inc. (1.28%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, David D Meek, Henry J Fuchs, Isan Chen, Jamie Christensen, Julie M Cherrington, Julie M Cherrington, Ltd Braslyn, Maria E Martinez and Vickie S Reed.
View institutional ownership trends.
How do I buy shares of Mirati Therapeutics?: Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Mirati Therapeutics' stock price today?: One share of MRTX stock can currently be purchased for approximately $37.65.
How much money does Mirati Therapeutics make?: Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $2.19 billion and generates $12.44 million in revenue each year. The biotechnology company earns $-740,870,000.00 in net income (profit) each year or ($13.18) on an earnings per share basis.
How many employees does Mirati Therapeutics have?: The company employs 413 workers across the globe.
Does Mirati Therapeutics have any subsidiaries?: The following companies are subsidiares of Mirati Therapeutics: MethylGene, MethylGene Inc., and Mirati Therapeutics B.V..
Read More
How can I contact Mirati Therapeutics?: Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com.

This page (NASDAQ:MRTX) was last updated on 3/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Mirati Therapeutics - MRTX Stock Forecast, Price & News

Mirati Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Mirati Therapeutics (NASDAQ:MRTX) Stock

MRTX Stock News Headlines

MRTX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

MRTX Stock - Frequently Asked Questions

Overall MarketRank^™